MTOR and gastric cancer: Specifically, treatment of CLDN18.2-positive gastric cancer cells with αCLDN18.2-MMAE led to a decreased phosphorylation of Akt, mTOR, and two critical downstream effectors, 4E-BP1 and p70S6K [32], indicating the inactivation of the Akt/mTOR pathway.